Alnylam Pharmaceuticals (ALNY) Operating Expenses (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Operating Expenses data on file, last reported at $1.1 billion in Q2 2026.

• Quarterly Operating Expenses rose 34.13% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.8 billion (up 43.99% YoY) and the FY2025 annual result came in at $3.2 billion, up 32.46% from the prior year.
• Operating Expenses grew to $1.1 billion in Q2 2026, from $898.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.1 billion in Q2 2026 to a low of $360.0 million in Q1 2022.
• A 5-year average of $640.5 million and a median of $566.1 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses dropped 1.05% — and 2026, when it surged 55.97%.
• Tracing ALNY's Operating Expenses over 5 years: stood at $523.6 million in 2022, then grew by 6.2% to $556.1 million in 2023, then rose by 25.57% to $698.3 million in 2024, then jumped by 38.23% to $965.3 million in 2025, then climbed by 9.76% to $1.1 billion in 2026.
• The last three Operating Expenses figures came in at $1.1 billion (Q2 2026), $898.5 million (Q1 2026), and $965.3 million (Q4 2025), per Business Quant data.